We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 35.50 | 35.40 | 35.60 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.25 | 106.45M |
From Apr 2019 to Apr 2024
TIDMFUM
RNS Number : 5755Y
Futura Medical PLC
06 March 2017
For immediate release 6 March 2017
Futura Medical plc
("Futura" or the "Company")
MED2002 Additional Patent Filing
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that it has filed a new formulation patent with the UK Intellectual Property Office in connection with MED2002, the Company's novel topical gel for the treatment of erectile dysfunction.
This patent application has the potential to extend MED2002's patent life worldwide through to 2038, thereby significantly increasing the opportunity for licensing partners to generate higher revenues and profits from the commercialisation of MED2002.
The new patent includes intellectual property confirmed by the Company's pivotal efficacy study of MED2002, the results of which were announced in September 2016.
MED2002's current patent protection runs until August 2028 in the USA and August 2025 in Europe.
James Barder, Futura's Chief Executive, commented: "This latest patent filing has the potential to extend MED2002's patent protection worldwide through to 2038, significantly extending the product's commercial window and increasing its attractiveness to licensing partners."
This announcement contains inside information.
For further information please contact:
Hot Features
Premium
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0) 1483 685
670
Email to: james.barder@futuramedical.com www.futuramedical.com
N+1 Singer (Nominated
Adviser and Broker)
Aubrey Powell / Liz Yong Tel:+44 (0) 20 7496 3000
For media enquiries please
contact:
Buchanan
Mark Court / Sophie Cowles Tel: +44 (0) 20 7466
/ Stephanie Watson 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCJFMFTMBJMMLR
(END) Dow Jones Newswires
March 06, 2017 02:00 ET (07:00 GMT)
1 Year Futura Medical Chart |
1 Month Futura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
